Lake Street Capital Lowers Ekso Bionics (NASDAQ:EKSO) Price Target to $2.00

Ekso Bionics (NASDAQ:EKSO) had its price target cut by Lake Street Capital from $2.50 to $2.00 in a report issued on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. StockNews.com initiated coverage on shares of Ekso Bionics in a research note on Saturday, October 26th. They issued a “hold” rating on the stock. HC Wainwright dropped their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday.

Ekso Bionics Price Performance

NASDAQ:EKSO opened at $0.86 on Tuesday. The company has a 50 day moving average price of $1.11 and a 200-day moving average price of $1.15. Ekso Bionics has a 1-year low of $0.83 and a 1-year high of $3.13. The company has a quick ratio of 1.77, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. During the same period in the previous year, the company posted ($0.24) EPS. Analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Institutional Trading of Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.